Literature DB >> 21037487

Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.

Safa Najafi1, Gholamreza Esmaeeli Djavid, Neda Mehrdad, Elahe Rajaii, Nasrinsadat Alavi, Aseih Olfatbakhsh, Masomeh Najafi, Alireza Bahrami, Kazem Heidari.   

Abstract

OBJECTIVE: The objective of our study was to show the impact of different chemotherapy regimens on the incidence of amenorrhea (chemotherapy-induced amenorrhea [CIA]) in premenopausal women of various ages with breast cancer.
METHODS: This is a follow-up study of 226 premenopausal women with breast cancer who had received one of three chemotherapy regimens: conventional (cyclophosphamide/methotrexate/5-fluorouracil), anthracycline based, and anthracycline-taxane based. They were evaluated for the incidence of CIA in the follow-up clinic of the Iranian Center for Breast Cancer. A statistical analysis using SPSS software was performed, and logistic regression and Cox regression model were used to determine the risk factors for CIA.
RESULTS: Of the 226 women with a median age of 40 years (range, 26-56 y) who participated in this study, 154 (68.1%) developed CIA. In 101 (65.6%) of these women, CIA was established. CIA was present in 52.5% of the women who had been treated with conventional regimens (cyclophosphamide/methotrexate/5-fluorouracil), 66.7% of the women who had been treated with anthracycline, and 78.7% of the women who had been treated with anthracycline-taxane. Therefore, the frequency of CIA was significantly higher in the taxane-based chemotherapy group than in the other groups (P = 0.015). Although a slightly higher incidence of CIA in women with hormone-insensitive tumors (estrogen receptor negative and progesterone receptor negative) versus hormone-sensitive tumors (estrogen receptor positive and progesterone receptor positive) who had been treated with combination regimens was observed, no statistically significant difference was found (P = 0.629). Of all of the risk factors that were evaluated in the study, anthracycline-taxane-based regimens (odds ratio, 4.059; 95% CI, 1.6-9.8) and age older than 40 years (odds ratio, 3.5; 95% CI, 1.9-6.6) were the most important factors in the development of CIA.
CONCLUSIONS: The type of chemotherapy and the age of the woman at the onset of breast cancer are the most important risk factors in CIA. Taxane-based regimens induced more CIA than did other regimens.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21037487     DOI: 10.1097/gme.0b013e3181f3e6e7

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  6 in total

1.  Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Authors:  Kathryn J Ruddy; Hao Guo; William Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Clifford Hudis; Ian E Krop; Harold J Burstein; Eric P Winer; Ann H Partridge; Sara M Tolaney
Journal:  Breast Cancer Res Treat       Date:  2015-05-16       Impact factor: 4.872

2.  The risk of amenorrhea is related to chemotherapy-induced leucopenia in breast cancer patients receiving epirubicin and taxane based chemotherapy.

Authors:  Wenbin Zhou; Qiang Ding; Xiuqing Liang; Zhongyuan He; Xiaoming Zha; Xiaoan Liu; Shui Wang
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

3.  Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients.

Authors:  Se Jeong Jeon; Jae Il Lee; Myung Jae Jeon; Maria Lee
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.

Authors:  Toralf Reimer; Sarah Kempert; Bernd Gerber; Hans-Jürgen Thiesen; Steffi Hartmann; Dirk Koczan
Journal:  BMC Cancer       Date:  2016-05-27       Impact factor: 4.430

5.  The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients.

Authors:  Ingeborg J H Vriens; Ashley J R De Bie; Maureen J B Aarts; Maaike de Boer; Irene E G van Hellemond; Joyce H E Roijen; Ron J T van Golde; Adri C Voogd; Vivianne C G Tjan-Heijnen
Journal:  Oncotarget       Date:  2017-02-14

6.  Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal Women With Breast Cancer: An Updated Meta-Analysis.

Authors:  Yifei Wang; Yaming Li; Jingshu Liang; Nan Zhang; Qifeng Yang
Journal:  Front Oncol       Date:  2022-04-05       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.